CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹7,014 Cr | ₹5,484 Cr | ₹5,246 Cr | ₹5,033 Cr | ₹4,913 Cr |
What is the latest Total Current Liabilities ratio of CIPLA ?
| Year | Total Current Liabilities |
|---|---|
| Mar2026 | ₹7,014 Cr |
| Mar2025 | ₹5,484 Cr |
| Mar2024 | ₹5,246 Cr |
| Mar2023 | ₹5,033 Cr |
| Mar2022 | ₹4,913 Cr |
How is Total Current Liabilities of CIPLA Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹7,014 Cr | 27.89 | |
| Mar2025 | ₹5,484 Cr | 4.54 | |
| Mar2024 | ₹5,246 Cr | 4.22 | |
| Mar2023 | ₹5,033 Cr | 2.45 | |
| Mar2022 | ₹4,913 Cr | - | |
Compare Total Current Liabilities of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹111,809.3 Cr | -2.1% | -5.2% | -11.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹451,339.0 Cr | -2.7% | -3.7% | 20.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹254,068.0 Cr | 3.7% | 15.7% | 51% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹188,767.0 Cr | -0.8% | 1% | 36.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,113.4 Cr | -0.8% | -0.5% | -9.3% | Stock Analytics | |
| MANKIND PHARMA | ₹95,242.0 Cr | -3.1% | -5.4% | -9.3% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | -2.1% |
-5.2% |
-11.6% |
| SENSEX | -1.8% |
-3.7% |
-5.7% |
You may also like the below Video Courses